Metal complexes synthesis and properties

Platinum-based drugs like cisplatin have been cornerstones of cancer chemotherapy for decades, yet their clinical use is frequently undermined by acquired resistance and significant side effects, motivating researchers to understand precisely how these compounds interact with DNA and trigger cell death at the molecular level. By mapping the structural and chemical basis of those interactions, scientists hope to explain why some tumors stop responding to treatment and to identify targets for overcoming that resistance. A parallel effort focuses on developing entirely new classes of metal complexes—particularly those built around ruthenium—that may damage cancer cells through distinct mechanisms, potentially sidestepping the toxicity and resistance profiles that limit platinum drugs. Central open questions include how cells recognize and repair metal-induced DNA lesions, and whether non-platinum compounds can be tuned with sufficient selectivity to advance from laboratory promise into viable clinical therapies.

Works

145,269

Total citations

2,284,790

Keywords

Platinum-Based DrugsCisplatin ResistanceMetal ComplexesAnticancer AgentsMolecular MechanismsDNA Interactions